Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Coffee Drinkers Have Lower Risk of Getting Autoimmune Liver Disease

By BiotechDaily International staff writers
Posted on 29 May 2013
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, according to new research.

The new findings were presented May 2013 at the Digestive Disease Week 2013 Conference, held in Orlando (FL, USA). PSC is an inflammatory disease of the bile ducts that results in inflammation and subsequent fibrosis that can lead to cirrhosis of the liver, biliary cancer, and liver failure.

“While rare, PSC has extremely detrimental effects,” said study author Craig Lammert, MD, a Mayo Clinic (Rochester, MN, USA) gastroenterologist. “We’re always looking for ways to mitigate risk, and our first-time finding points to a novel environmental factor that also might help us to determine the cause of this and other devastating autoimmune diseases.”

The study examined a large group of US patients with PSC and primary biliary cirrhosis (PBC) and a group of healthy patients. Data showed that coffee consumption was linked with a lower risk of PSC, but not PBC. PSC patients were much apt not to drink coffee than healthy patients were. The PSC patients also spent almost 20% less of their time routinely drinking coffee than the control group.

The study suggests PSC and PBC vary more than originally believed. Konstantinos Lazaridis, MD, a Mayo Clinic hepatologist and senior author of the study, remarked, “Moving forward, we can look at what this finding might tell us about the causes of these diseases and how to better treat them.”

Related Links:

Mayo Clinic



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.